Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Florian, A; Machler, H; Renz, D; Zimpfer, D.
Left ventricular assist device - an update
J KARDIOL. 2022; 29(9-10): 258-262.
Web of Science
- Führende Autor*innen der Med Uni Graz
- Florian Alissa
- Zimpfer Daniel
- Co-Autor*innen der Med Uni Graz
- Mächler Heinrich
- Altmetrics:
- Abstract:
- The prevalence of heart failure is expected to increase due to current demographic trends and improved survival rates for cardiac diseases. Left ventricular assist devices (LVADs) have become a standard therapy for terminal heart failure and are used in the indications,bridge to transplant" and,destination therapy". An LVAD is a cardiac assist device designed for left heart failure that can replace the left ventricle partially or completely. The device consists of a battery-powered mechanical pump, which draws blood from the left ventricle and pumps it into the aorta. The implantation can be performed minimally invasive without sternotomy in the majority of patients. The optimal time for implantation is determined on an individual basis by an interdisciplinary,Heart Failure Team". Both the European and the U.S. guidelines follow the INTERMACS classification for the treatment of patients with inotropic therapy, recurrent cardiac decompensation, and severe exercise intolerance. Early referral to a heart failure outpatient clinic plays a central role. With the modern systems, 2-year survival rates of > 80% can be achieved, similar to heart transplantation. Overall, as a result of technical improvements, the complication rate of LVAD therapy has decreased significantly. The main issues are hemocompatibility problems (strokes, bleeding) and, if the indication is given too late, right heart failure.
- Find related publications in this database (Keywords)
- left ventricular assist device
- LVAD
- indications
- results
- future aspects